Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...
Investor's Business Daily on MSN
Leading drug stock fights to regain buy point at key resistance level
Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego.
The Centers for Medicare & Medicaid Services extended a safety net to older Americans by announcing significant price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback